@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP464454.RAI5VSzatl4PcF3r3zXSP8KZVTJgd4k630x6CNPsZJtrU130_head { this: np:hasAssertion dgn-np:NP464454.RAI5VSzatl4PcF3r3zXSP8KZVTJgd4k630x6CNPsZJtrU130_assertion; np:hasProvenance dgn-np:NP464454.RAI5VSzatl4PcF3r3zXSP8KZVTJgd4k630x6CNPsZJtrU130_provenance; np:hasPublicationInfo dgn-np:NP464454.RAI5VSzatl4PcF3r3zXSP8KZVTJgd4k630x6CNPsZJtrU130_publicationInfo; a np:Nanopublication . dgn-np:NP464454.RAI5VSzatl4PcF3r3zXSP8KZVTJgd4k630x6CNPsZJtrU130_assertion a np:Assertion . dgn-np:NP464454.RAI5VSzatl4PcF3r3zXSP8KZVTJgd4k630x6CNPsZJtrU130_provenance a np:Provenance . dgn-np:NP464454.RAI5VSzatl4PcF3r3zXSP8KZVTJgd4k630x6CNPsZJtrU130_publicationInfo a np:PublicationInfo . } dgn-np:NP464454.RAI5VSzatl4PcF3r3zXSP8KZVTJgd4k630x6CNPsZJtrU130_assertion { miriam-gene:920 a ncit:C16612 . lld:C0524909 a ncit:C7057 . dgn-gda:DGN156ca7da8587797664dc31e5be2e738e sio:SIO_000628 miriam-gene:920, lld:C0524909; a sio:SIO_001121 . } dgn-np:NP464454.RAI5VSzatl4PcF3r3zXSP8KZVTJgd4k630x6CNPsZJtrU130_provenance { dgn-np:NP464454.RAI5VSzatl4PcF3r3zXSP8KZVTJgd4k630x6CNPsZJtrU130_assertion dcterms:description "[Of the patients, 49/255 (19.2%) developed advanced liver diseases (ALDs) (during 5.2 years): 30 patients developed clinically overt cirrhosis, 10 developed hepatocellular carcinoma and 9 developed severe reactivation of a preexisting chronic hepatitis B. Baseline CD4(+) cell count <200 cell/mm(3) (P = 0.013, OR = 6.503), baseline alanine aminotransferase (ALT) elevation (P = 0.011, OR = 14.456), and longer cumulated time with detectable HIV RNA (P = 0.008, OR = 1.814) and HBV DNA (P = 0.014, OR = 1.536) were risk factors for ALDs development, while CD4(+) cell count changes ≥150 cells/mm(3) within 3 months (P = 0.039, OR = 0.049) and the use of lamivudine-based cART (P = 0.030, OR = 0.034) were protective against ALDs development.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:21713428; prov:wasDerivedFrom dgn-void:befree-20140225; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-20140225 pav:importedOn "2014-02-25"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP464454.RAI5VSzatl4PcF3r3zXSP8KZVTJgd4k630x6CNPsZJtrU130_publicationInfo { this: dcterms:created "2014-10-02T12:36:36+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetrdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v2.1.0.0" . dgn-void:disgenetrdf pav:version "v2.1.0" . }